CVS

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✗

Return

-1.87%

Status

scored

Maintain CVS at ~1% portfolio weight with simplified bilateral tripwires, avoiding the multi-tier conditional complexity that caused the 10-02 NaN failure. Hard stop at $82.00, trim 25-30% into any squeeze to $90-91 without MACD/volume confirmation, and re-engage only on close above $93.28 with ≥8M volume. Q3 2026 earnings and mid-October MA Star Ratings are binary forcing functions requiring mandatory reassessment with hard-coded automatic exit if catalyst passes without re-decision.

Outcome

✓

Return

-0.17%

Status

scored

Maintain CVS at Hold rating with 4-of-5 position consensus; Aggressive dissents but prior 10-02 Overweight framework failed to execute (NaN alpha), making technical confirmation a prerequisite for any accumulation. Hard stop at $82.00 (below Sept 24 capitulation low of $85.05, above $80 support vacuum), trim trigger at $90-91 without MACD/volume confirmation, and re-engagement requires close above $97.02 (50 SMA) on ≥8M volume with MACD bullish cross and RSI >50. Q3 2026 earnings (early November) and mid-October MA Star Ratings release are binary forcing functions with mandatory reassessment.

Outcome

✗

Return

+1.76%

Status

scored

Maintain HOLD on CVS with a simplified mechanical framework designed for operational execution rather than multi-stage complexity. Hard stop triggers at weekly close below $79.50 (below $81.79 Bollinger lower band and $85.05 Sept 24 capitulation low); trim triggers on any squeeze to $92-94 zone without MACD confirmation. Re-engagement requires close above $97.02 on ≥8M volume with MACD bullish cross and RSI >50. Q3 2026 earnings and mid-October MA Star Ratings are binary forcing functions requiring mandatory reassessment with hard-coded auto-exit if catalyst passes without re-decision.

Outcome

✓

Return

-0.67%

Status

scored

Maintain HOLD on CVS at $86.46, preserving the defensive stub (3.12% dividend yield, 2.4x FCF coverage) while committing to a mechanical $84.00 hard stop if the 200 SMA remains contested without reclaim. Use March 2027 $80 puts as cheap portfolio insurance rather than adding directional exposure ahead of the Q3 2026 earnings binary event.

Outcome

–

Return

+0.64%

Status

scored

Initiating Overweight with staged accumulation (0.5-0.75% Layer 1 at current $84-86, 0.5-0.75% Layer 2 at $80-82 reversal confirmation, 0.5% Layer 3 post-Q3 earnings) capped at 2.0% total position to break the pattern of six consecutive Hold failures. The fundamental case is asymmetric (10.1x forward P/E, 0.20 PEG, $14-16B sustainable FCF, real deleveraging from $76.3B to $50.1B net debt), but the 200 SMA breakdown and binary Q3 catalyst warrant smaller-than-benchmark sizing with a hard stop at $76 weekly close.

Outcome

✓

Return

+1.48%

Status

scored

Maintain CVS at ~1% portfolio NAV (below 2-3% benchmark) as a defensive stub through Q3 2026 earnings and mid-October MA Star Ratings, with hard stop at $81.50 and weekly close below $82.65 triggering automatic full exit; trim 25-30% on any squeeze into $90-91 resistance without confirmation.

Outcome

–

Return

-0.57%

Status

scored

Trim CVS to ~1% portfolio weight (below 2-3% benchmark) via 25-30% reduction at current $87.10 within 1-2 sessions, with remaining position sized defensively using a structural stop at $83.40 on volume >10M shares; re-engagement requires close above $97.02 on volume ≥8M shares with MACD histogram contracting toward zero and RSI >50. The Underweight rating reflects consensus across all three analysts on trim direction, with the Q3 2026 earnings (late Oct/early Nov) and 11/04/2026 election serving as mandatory reassessment points.

Outcome

✓

Return

-1.62%

Status

scored

Trim CVS to approximately 1% portfolio weight (below the 2-3% benchmark) as a trim-and-defend posture ahead of the 11/04/2026 election binary, reducing from current exposure via 25-30% market trim near $87 executed within 1-2 sessions. The hard structural exit trigger is a weekly close below $86.71 on volume exceeding the 20-day average, which would open a measured move toward March 2026 lows near $69.50 (representing approximately 22% downside); re-engagement is conditioned on closing above $97.02 with volume ≥8M shares, MACD histogram contracting toward zero, and RSI >50.

Outcome

✓

Return

-0.85%

Status

scored

Maintain Hold on CVS at ~$87.85 with active execution framework, not passive carry—do not initiate or add positions at current levels. Re-engage only on confirmed close above 50 SMA at $97 on ≥15M shares volume AND clean 2027 quantification at Q3 2026 earnings, while using $84.43 close-based stop (lower Bollinger band) as automatic trim signal and $70.93 as major exit; forced reassessment mandatory at Q3 print to prevent indefinite Hold drift.

Outcome

✓

Return

-1.44%

Status

scored

Maintain existing CVS exposure at ~$89.13 without adding fresh longs; tactical starter positions (≤1/3 normal size) allowed only on confirmed close above $92.64 with volume ≥1.5x average and successful higher-low retest at $90-91. Hard stop at $86.71 (200 SMA) on close-based volume >10M shares. Scale-up beyond starter contingent on 2027 headwind quantification (<$1.00 EPS impact) and sustained FCF above $3B quarterly run-rate.

Outcome

✗

Return

+4.80%

Status

scored

Reduce CVS exposure by 65-70% total through a two-stage exit: 50% at market ($85.05) within 1-2 sessions, then an additional 15-20% via limit orders if price squeezes toward the $89-$91 confluence zone (10 EMA/Bollinger middle band); hedge the remaining stub with $80 strike protective puts (3-6 month tenor) and stop out the residual at $80.50 close-based.

Outcome

✓

Return

-0.94%

Status

scored

Maintain CVS HOLD at $86.86 with active execution framework rather than passive positioning; hard stop at $83.50 with pre-committed trim triggers if 200 SMA fails to reclaim within 5-7 sessions. The balanced setup reflects genuine valuation merit (10x forward P/E, $7.8B FCF) alongside documented structural risks (310bps margin compression, $5.7B impairment), requiring disciplined conditional action through Q3 binary catalyst in late October.

Outcome

✓

Return

-1.42%

Status

scored

Analysts recommend trimming 40-50% of CVS exposure at $87.10 or on any squeeze toward $94-95, executing 25% at market within 1-2 sessions and 15-25% via limits over 10 sessions, capping residual at 1.5-2% of NAV. Hard structural stop set at $86.52 close-based on volume above 20-day average triggering automatic downgrade to Sell and full exit, with re-engagement only on confirmed close above $91.08 on 8M+ shares with MACD contracting and RSI above 45.

Outcome

✓

Return

-0.57%

Status

scored

Maintain CVS at $87.60 with HOLD rating, as the stock sits only $1.14 above the untested 200-day SMA ($86.46) with RSI 27, no bullish divergence, and expanding negative MACD on distribution volume. Execute a collar hedge (sell upside calls against protective puts) to carry through the Q3 2026 binary catalyst in ~4 weeks, the first clean YoY comparison post-PDP divestiture. Hard stop at $84.50 on closing basis.

Outcome

✓

Return

-1.40%

Status

scored

Trim 40-50% of CVS exposure (high end per 2026-09-15 sizing lesson), executing 25% at market within 1-2 sessions and 25% via limit orders at $94-95. Retain 50-60% stub capped at 1.5-2% of NAV with $85 strike protective puts (60-90 day expiry) and covered call overlay at 92-95 strike October calls. Hard stop at $86.40 close with volume >20-day average triggers automatic Sell downgrade; re-engage only on confirmed close >$92.94 with volume ≥8M and MACD histogram contracting toward zero. Reassess at Q3 2026 earnings and September FOMC; price target $86.00.

Outcome

✓

Return

-1.58%

Status

scored

Trim CVS to 50-60% of benchmark weight (meaningful underweight) at current levels ($90.27) or on any squeeze toward $94.50, with hard structural stop at $86.34 close-based on volume >20-day average triggering full exit. Re-engagement requires confirmed close >$94.50 with RSI >50 AND MACD histogram expanding positive. Covered call overlay (sell 92-95 strike October calls) recommended against retained stub. Mandatory reassessment at Q3 2026 earnings and September FOMC meeting.

Outcome

✓

Return

-1.58%

Status

scored

Reduce CVS by 50% in two tranches: 25% at market within 1-2 sessions and 25% via limit orders in the $94.50-$95.50 zone. Retain ~50% as a defensive stub with a hard stop at $86.28 (200 SMA close-based), below which full exit is mandatory. Re-engagement requires confirmed close above $99.37 on volume ≥8M shares with MACD positive crossover and RSI above 55.

Outcome

✓

Return

-2.93%

Status

scored

The analysts recommend trimming 35% of CVS exposure at $94-96 or on any squeeze toward $97-99, escalating from the prior cycle's insufficient 15-20% reduction, with a hard stop at $91.68 below which full exit is mandatory. Re-engagement requires a confirmed close above $99.92 on volume ≥8M shares with MACD positive crossover and RSI >55, with mandatory reassessment at Q3 2026 earnings and September FOMC.

Outcome

✓

Return

-1.11%

Status

scored

Trim CVS position 15-20% to reduce exposure to ~60-70% of benchmark weight, avoiding the aggressive 25-40% trim that risks whipsaw in the $2.38 ATR basing pattern. Hard structural floor is the 200 SMA at $86.03; re-engagement requires confirmed close above $99.92 with volume >8M and positive MACD crossover. Mandatory reassessment at September FOMC meeting and Q3 2026 earnings (late Oct/early Nov).

Outcome

✗

Return

+0.94%

Status

scored

Reduce CVS exposure by trimming 40-50% of the position at the $98-100 resistance zone where the declining 50 SMA has repeatedly rejected price, while retaining the residual 50-60% with a closing stop at $92.50 (between the swing low and lower Bollinger Band); mandatory reassessment is required at both the September FOMC meeting and Q3 2026 earnings, with re-entry conditioned on either post-FOMC stabilization without medical-cost deterioration or a confirmed close above $100 on volume exceeding 7M with MACD positive crossover. Put hedges at $90-92 strike (60-90 day expiry) are recommended only if practical constraints prevent full trim execution, as the analysts deemed theta decay on purchased puts redundant given the capital efficiency of outright reduction.

Outcome

✓

Return

-0.66%

Status

scored

CVS is rated Underweight with a $92 price target and 4-6 week time horizon through Q3 2025 earnings. The strategy calls for trimming to minimum-weight on rallies into the $97–$100 zone while avoiding fresh short exposure at current levels, with a hard stop at $92.79 and structural invalidation at the $85.83 200 SMA level. Re-entry triggers include confirmed close above $100.26 on volume ≥8M with RSI >55 and positive MACD, or capitulation flush to $85–$88 with RSI <30.

Outcome

–

Return

-0.09%

Status

scored

CVS is downgraded to Underweight with a recommendation to trim approximately one-third of positions immediately in the $96-97 range rather than waiting for a rally, with a hard stop at $92.85. Re-entry requires both a confirmed close above $100.41 on volume of at least 8 million shares and a MACD positive crossover with RSI above 55. A mandatory reassessment is set for Q3 2026 earnings in late October/early November, where medical cost trends and Aetna MLR will determine whether the Underweight thesis fully plays out.

Outcome

✓

Return

-0.72%

Status

scored

Maintain CVS at benchmark weight (HOLD) at $96.74, rejecting aggressive adds due to unconfirmed momentum (MACD still negative at -1.04) and asymmetric risk in the $96-100 chop zone ahead of binary Q3 PBM earnings. Pre-committed binary triggers govern action: incremental add only on confirmed close above $100.56 with volume ≥8M and positive MACD, OR staged accumulation at $85-90 on 200 SMA retest that holds. Hard stop at $91.54 close-based; mandatory reassessment at Q3 2026 earnings where Aetna MLR and Caremark margins determine directional resolution.

Outcome

–

Return

-0.69%

Status

scored

Analysts converge on a constructive setup for CVS but disagree on sizing; the recommended framework uses a 40-50% starter allocation at ~$97 with a hard stop at $92, scaling to ~70% on confirmed close above $100.71 with volume ≥8M, RSI >55, and MACD positive. Full Overweight weight is deferred until post-Q3 2026 earnings validation, respecting the alpha-destructive pattern of scaling into chop zones ahead of binary catalysts while capturing Q2'26's strong operating recovery (revenue +7.3% YoY, operating income +$4.70B, FCF $5.65B) at 11.4x forward P/E.

Outcome

✓

Return

-0.47%

Status

scored

Maintain CVS at benchmark weight with a HOLD rating as the stock remains in the $96–100 chop zone where the aggressive analyst's entry criteria have not triggered. The risk-reward math is unfavorable (downside to $92.50 stop is $4.73 vs upside to $100.79 target of only $3.56), and adding ahead of Q3 2026 earnings catalyst without confirmed technicals violates the discipline that produced +4.6% alpha on 8/31. Pre-committed binary triggers must fire before incremental position addition.

Outcome

✓

Return

-0.03%

Status

scored

Analysts recommend trimming CVS positions to 55-65% weight given an asymmetric risk-reward (resistance at $101 is only 3.5% above vs. support at $92.90, which sits 4.7% below), combined with 11.4x P/E built on self-guided EPS of $7.90-$8.10, $76B debt, and $85.5B goodwill impairment risk. The recommended re-engagement triggers are a close above $101 on volume exceeding 10M shares or a pullback to the $85-$88 zone, with mandatory reassessment at Q3 2026 earnings.

Outcome

✓

Return

-0.38%

Status

scored

Maintain CVS (CVS) at HOLD with current weight, rejecting both the aggressive analyst's recommendation to add at attractive multiples and the conservative analyst's deeper bearish tilt. The position remains in the explicit $96-100 chop zone where the prior plan forbids scaling in, with pre-committed binary triggers: 50% incremental add on confirmed close >$101.01 with volume ≥12M shares, staged adds at $85-88 on 200 SMA zone test, 25-30% trim on close <$92.85, and 50% cut on close <$89.91. The binding catalyst is Q3 2026 earnings, where Aetna MLR, Caremark margins, and forward guidance will determine directional resolution.

Outcome

✗

Return

+3.93%

Status

scored

Maintain CVS at Hold rating with $102 price target over 2-3 quarters. Dual-stop structure set at $85.15 (200 SMA thesis-failure stop) and $89.33 (2× ATR tactical stop) with scaling triggers at $94.20, $95.71, and $101.02 for potential position increases on confirmed momentum strength. Mandatory reassessment at Q3 2026 earnings.

Outcome

✗

Return

+0.91%

Status

scored

The analysts recommend trimming 30–35% of the CVS position across three price levels ($92.50, $93.00–$93.20, $93.50), citing the heroic $8.51 forward EPS (32% above the $6.47 all-time high), weak 1.4% sequential Q1→Q2 2026 net income growth, and PBM regulatory risk. A hard stop is set at $83.50 with tiered re-entry triggers at $88–88.50 (40%), $94–95 (40%), and $101 (20%) on verified technical signals, requiring mandatory reassessment at Q3 2026 earnings.

Outcome

✓

Return

+0.15%

Status

scored

Maintain CVS at benchmark weight (Hold) as the neutral technical setup and unproven $8.51 EPS thesis prevent adding exposure, while the structural floor at $85.06 (200 SMA) and 2.82% dividend yield with low beta (0.596) justify holding rather than trimming. Use a $87.50 close-based stop to define risk in the $2.35 ATR environment, with pre-committed triggers for upgrade on $88-90 reversal with RSI divergence or downgrade on confirmed close below $88.30.

Outcome

✓

Return

-1.48%

Status

scored

Analysts recommend holding CVS (CVS) at current levels, with the neutral synthesis prevailing over both aggressive and conservative positions. The Q3 2026 earnings represents the binary catalyst where an optical beat is likely given easy comps, but underlying MA medical cost deterioration and segment margin stability will determine post-print reaction. Stop discipline is critical at $91.50, with $92.90 support tested three times and the 200 SMA at $84.98 as the structural break level.

Outcome

✗

Return

+1.53%

Status

scored

Maintain Underweight rating on CVS with a measured 25-30% trim over 2-3 sessions, executed into relief bounces toward $94-97 rather than at current breakdown lows. Hard structural stop is $84.89 (200 SMA daily close), with $85-strike puts recommended for convex bearish exposure rather than further equity reduction. The 25-30% trim range balances prior post-mortem findings that 40%+ trims destroy alpha while preserving meaningful residual (~0.5% NAV cap) to capture dividend carry and defensive beta cushion.

Outcome

✓

Return

-1.29%

Status

scored

MAINTAIN HOLD on CVS as the structural floor (200 SMA at $84.81, 2.86% dividend yield, ~2.4x dividend coverage, $7.6B+ deleveraging) remains intact despite -11.7% post-beat decline and bearish catalysts (negative TBV, $85.5B goodwill at 71% of market cap). Deploy cash-secured puts at $80 strike to harvest premium and define downside entry without reducing equity exposure—the five prior Underweight/Hold decisions all produced alpha leakage when equity was reduced. HARD TRIGGER: confirmed daily close below $84 on volume → trim 50-75%.

Outcome

✗

Return

+1.17%

Status

scored

Maintain Underweight rating on CVS with a ~25% equity trim (lower end of the trader's 25-40% range), keeping residual at ~0.5% NAV; adopt the neutral analyst's $87.50 stop (one ATR buffer below the 200 SMA) rather than the trader's tighter $84.50, and route additional bearish expression through the existing $85-strike puts hedge rather than compounding equity reduction, given four of five prior Underweight calls leaked alpha due to defensive-floor absorption.

Outcome

✓

Return

-0.67%

Status

scored

Maintain Underweight rating with the ~0.5% NAV cap established on 8/19; do NOT layer an additional 30–50% equity trim on top of the 8/18 trim, as three prior Underweight decisions on CVS have validated this pattern as alpha-destructive. Route any additional bearish expression through the existing $85-strike puts hedge rather than further equity reduction. Mental stop at $89.50 (lower Bollinger) on rising volume; hard structural stop at $84.50 (200 SMA) on a daily close.

Outcome

✗

Return

0.00%

Status

scored

Maintain Underweight rating with the existing ~0.5% NAV cap established on 8/18, rejecting additional equity trimming that would compound to ~65-70% total reduction—a pattern validated as alpha-destructive across three prior Underweight calls. Route any additional bearish expression through the existing $85-strike put hedge rather than further equity reduction; the hard exit remains a daily close below $84.50 (200 SMA), with re-evaluation tied to Q3 2026 earnings (≥$2.4B net income with margin stabilization) or a confirmed $101.79 reclaim on expanding volume.

Outcome

✓

Return

-1.33%

Status

scored

Maintain an Underweight rating on CVS with a directive to trim 40-50% of the position at current ~$95 levels over the next 1-2 sessions, capping the residual at 0.5% of NAV—tighter than the prior 0.75% framework—while preserving the $85 strike puts as downside protection; mandatory reassessment at Q3 2026 earnings in late October, with upgrade to Hold contingent on net income ≥$2.4B and margin stabilization, and downgrade to Sell triggered by a daily close below $89.50 on rising volume or weekly close below $84.46 confirming structural breakdown.

Outcome

✗

Return

+0.96%

Status

scored

CVS is rated Underweight with a recommendation to trim 25-35% immediately, capping residual exposure at 0.75% of portfolio NAV (half the normal healthcare allocation). The rating reflects deteriorating Q2 margins despite flattering headline net income, an 11.1x forward P/E contingent on unproven EPS, and structural balance sheet risks including $76B lease-adjusted debt and negative tangible equity, with the 200 SMA at $84.38 serving as the full-exit stop. A 2-of-4 re-engagement framework and 3-6 month $85 strike puts on 1-2% of the position hedge the Q3 binary without forcing full equity exit.

Outcome

✗

Return

-3.24%

Status

scored

Maintain CVS at Hold with a price target of $110.00, collecting the 2.81% dividend yield while awaiting Q3 2026 earnings resolution. Downgrade to Underweight if the stock closes below $93.00 on elevated volume; upgrade to Overweight on a confirmed close above $102.39 with rising volume and positive MACD divergence. The key tension is management's $8.50 EPS guide versus the $9.20 H1 annualized run rate, where the conservative analyst correctly notes $2.5B of the OCF improvement is working-capital release that reverses, making the guidance more consistent with foresight of softness than sandbagging.

Outcome

✓

Return

+2.28%

Status

scored

Initiate phased accumulation of CVS toward an Overweight position with full deployment at 3-4% portfolio weight, deploying a 1-1.3% starter tranche at ~$95, a second tranche at ~$91.58 (Bollinger lower band), and reserving a third tranche for the $84-85 200-SMA zone; hard stop at $84 daily close (regime change trigger), targeting $111-115 mean reversion in 2-3 quarters while collecting the 2.81% dividend yield as carry.

Outcome

✓

Return

+0.29%

Status

scored

Maintain CVS at or below benchmark weight while avoiding additions into the confirmed downtrend; await either a mean-reversion trigger (close above 50 SMA at $101.62 with positive MACD histogram) or a deeper value entry near the 200 SMA zone at $84-86. Hard stop placed at $83.50 (just below the 200 SMA at $84.15), with any tactical add capped at half benchmark weight on confirmed trigger. Re-evaluate the Hold posture if neither trigger fires within 60-90 days by mid-November 2026.

Outcome

–

Return

+1.30%

Status

scored

Reduce CVS by 40-50% given broken technical structure (price below 10 EMA, 50 SMA, and lower Bollinger with RSI collapsed to 32), fragile 2027 EPS consensus ($8.49) facing realistic downside to $6.50-$7.00, and zero buybacks for four consecutive quarters signaling insider skepticism. Retain a defensive core to collect the 2.78% dividend while preserving capital for higher-quality setups.

Outcome

✗

Return

-2.27%

Status

scored

All three analysts converge on Hold, with the neutral analyst providing the clearest synthesis: even a 12% EPS haircut to $7.50 leaves CVS at 12.8x earnings on a 2.78% yielder with accelerating FCF—cheap but not yet a catalyst. The aggressive analyst's pre-commitment to averaging into sub-$94 levels while maintaining an $84 stop is operationally incoherent, as the neutral analyst correctly exposed; stop discipline and averaging-in cannot coexist at the same price level. The recommendation is to maintain the current position at $101.46, collect the dividend, and wait for a single re-engagement trigger: confirmed reclaim of the 50-SMA at $101.46 on above-average volume with the MACD histogram turning less negative, using $84 as the hard structural stop.

Outcome

✓

Return

-0.03%

Status

scored

All three risk analysts converge on Hold, which validates the verdict — CVS sits in a "no-man's land" zone between lower-Bollinger resistance and mid-range support, so do not chase at $95.70. Accumulate only on weakness toward $90.50 with stop at $83.90 (just below the 200-DMA at $83.93), and scale up on capitulation flush to $88-90 or successful 50-day SMA reclaim at $101.40; the 2.76% dividend makes the wait productive.